Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?
Publication in refereed journal
CUHK Authors
Full Text
Digital Object Identifier (DOI) DOI for CUHK Users |
Altmetrics Information
.
Other information
AbstractEpstein–Barr virus (EBV)-based biomarkers are used for nasopharyngeal carcinoma (NPC) screening in endemic regions. A recent prospective study describes the use of a new serological biomarker, antibodies targeting the EBV protein BNLF2b, for NPC screening in >20,000 participants. This biomarker yielded both higher sensitivity and specificity for NPC detection in the screening cohort compared with the conventionally used antibodies. Herein, we highlight the key findings of this study and discuss the implications of these results.
Refers to Li, T. et al. Anti-Epstein–Barr virus BNLF2b for mass screening for nasopharyngeal cancer. N. Engl. J. Med. 389, 808–819 (2023).
Refers to Li, T. et al. Anti-Epstein–Barr virus BNLF2b for mass screening for nasopharyngeal cancer. N. Engl. J. Med. 389, 808–819 (2023).
All Author(s) ListLam WKJ, Chan ATC
Journal nameNature Reviews Clinical Oncology
Year2024
Month1
Volume Number21
Issue Number1
PublisherSpringer
Pages6 - 7
ISSN1759-4774
eISSN1759-4782
LanguagesEnglish-United Kingdom
